Air Doctor, a technology platform providing a global medical outpatient network that connects travelers with local doctors, has raised a Series A funding round of $7.8 million from Kamet Ventures – the AXA-backed venture builder – and The Phoenix Insurance Company.

Marion Surgical, which works with surgeons from around the globe to build a next generation suite of surgical simulators through virtual reality, has received a £280,000 investment from GC Angels, part of the Growth Company and an angel investor, alongside grant funding from Innovate UK, following an introduction from MIDAS, Manchester’s Inward Investment Agency.

The Canadian company enables surgeons to learn, collaborate, practice and share procedures in a realistic, safe, cloud-hosted environment through virtual reality. The company has recently set up a UK entity based at The Landing in MediaCityUK, Salford and has plans to relocate some of the Canadian team to the region as well as hiring locally.

A new medical device supplier which aims to offer UK hospitals the latest innovations from around the world has secured a £650,000 investment fromNPIF – Mercia Equity Finance, which is managed by Mercia and part of the Northern Powerhouse Investment Fund.

In December 2019 Backfinch invested c.£500,000 in London-based company Auro. Founded in 2016, Auro offers a fitness app that provides its users with tailored audio-based workouts. 

AstronauTx Ltd, a biotech company developing new medicines designed to restore the normal behaviour of astrocytes for the treatment of Alzheimer’s disease and other neurodegenerative diseases, has received £1 million of investment from the UCL Technology Fund to enable the development of translatable biomarkers for their drug discovery programs.  The UCL Technology Fund is a £53.3million investment fund that is co-managed by UCL Business and AlbionVC that invests in licensing projects and spinout companies arising from the UCL knowledge base.

LSP, the leading life sciences investor in Europe, has held its final close of LSP 6 at the $600 million hard cap. This is the largest fund ever raised in Europe focused on life sciences ventures. LSP currently has $1.1 billion of capital to invest across LSP 6, the LSP Health Economics Fund and LSP’s public fund and mandates.

Inotec AMD, a Cambridge based, fast-growing medtech business that has developed a novel device capable of healing complex chronic wounds, has secured investment of £7m. The funding round was led by Praetura Capital, with involvement from Boundary Capital.

The business has developed a world leading medtech product, called NATROX® Oxygen, for use in Wound Therapy. It generates pure humidified oxygen to treat a range of chronic wounds, from diabetic and venous ulcers to non-healing surgical wounds.

The o2h Therapeutics and AI Fund, hjas invested in Neurofenix, an innovative digital health company empowering stroke survivors and their families to get their life back.

The o2h Therapeutics and AI Fund, an early stage S/EIS fund investing in biotechnology therapeutics and related AI opportunities, has made an investment in Turbine, a simulation-based drug discovery company.

Based on a decade of research, Turbine’s biologists, bioinformaticians, data scientists, and AI engineers built the Simulated Cell. This platform is comprised of a dynamic computational model of the human cell and the underlying simulation technology to find the smartest route to novel targets, biomarkers, and combination therapies.

Award winnning Active Needle is seeking £150,000 for market entry.

Montis Biosciences announced its launch with €8.4 million in seed financing from an international investor syndicate.

Inotec AMD, a fast-growing medtech business that has developed an innovative device to heal and treat complex chronic wounds, has secured £7m in a funding round led by Praetura Ventures.  The business has developed Natrox, a cutting-edge product that uses pure humidified oxygen to treat a range of chronic wounds, from diabetic and venous ulcers to non-healing surgical wounds. Following several successful clinical trials, Inotec AMD is looking to expand its foothold in the US, Asia, the Middle East and Europe. The business currently provides products to the NHS and health providers in key markets including the US, Italy, Southeast Asia and the Middle East.